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Fabry’s disease (FD) is a lysosomal storage disorder associated with an alpha- galactosidase 
A deficiency. The prevalence of FD among juvenile idiopathic arthritis (JIA) patients with 
established diagnosis is unknown, but as musculoskeletal pain may be an important
complaint at presentation, misdiagnosed cases are anticipated. With this study, we aim to 
calculate the frequency of FD-associated mutations in a cohort of JIA patients. Children with 
JIA from a national cohort were selected. Clinical and laboratorial information was recorded 
in the Portuguese rheumatic diseases register (http://Reuma.pt). Molecular genetic testing 
to detect GLA gene mutations was performed. After the multiplex polymerase chain reac-
tions technique for DNA amplification, direct sequencing of the complete sequence of GLA 
gene was completed. From a cohort of 292 patients with JIA (188 females, 104 males), 
mutations were identified in 5 patients (all female). Four patients had the mutation D313Y, a 
rare GLA variant, which is associated with low enzymatic levels in plasma, but normal lyso-
somal levels. One patient presented the missense mutation R118C, which was previously 
described in Mediterranean patients with FD. This is the first screening of FD mutations in a 
cohort of JIA patients. No “classic” pathogenic FD mutations were reported. The late-onset 
FD-associated mutation, R118C, was found in a frequency of 0.34% (1/292).
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inTrODUcTiOn
Fabry’s disease (FD) is a lysosomal storage disorder initiated by sphingolipid accumulation within 
lysosomes owing to an alpha-galactosidase A (alpha-Gal A) deficiency (1, 2). It is a monogenetic 
defect inherited in an X-related recessive manner (3). The defects in the GLA gene are heterogeneous, 
with over 649 mutations recorded according to The Human Gene Mutation Database (accessed 27th 
October 2015); the majority of these mutations are missense or nonsense (4). This enzyme defect 
generates progressive accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids, 
primarily in the vascular endothelium (5).
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Reported FD incidences range from 1 in 476,000 to 1 in 
117,000 in the general population, and its estimated prevalence 
among males is around 1/40,000 (5, 6).
Classically, affected hemizygous males present with joint pain 
(60–80% of the patients), cutaneous lesions (angiokeratomas), 
and gastrointestinal (GI) symptoms (abdominal pain, diarrhea, 
and vomiting) (5, 7). Autonomic nerve system damage can appear 
early in the disease course, with patients reporting absence or 
decrease of sweating. Notwithstanding the absence of major 
organ dysfunction, these early symptoms, including arthralgia, 
can produce significant morbidity, limiting the quality of life of 
affected children (7).
During the course of the disease, more severe manifesta-
tions occur, including renal, cardiac, and cerebrovascular 
complications.
Contradicting a previous belief that women who are het-
erozygotic for disease causing mutations have a mild phenotype, 
an analysis from the Fabry Outcome Survey revealed that the 
majority of these females report clinical features of Fabry dis-
ease (8). Indeed, severe manifestations of disease were present, 
with 77% of women reporting neurological involvement, 59% 
cardiac involvement, and 40% renal involvement, although the 
onset of symptoms was not as early as is typically observed in 
males (9). A considerable delay between onset of symptoms and 
diagnosis in this group of women was also observed, underlin-
ing the importance of careful and longitudinal assessment of 
female heterozygote patients with FD (9). Recently, definite 
FD diagnostic criteria were defined, both for male and female 
patients (see Table S1 in Supplementary Material) (10).
Fabry’s disease is rare but causes high comorbidity and 
increases mortality. However, if early diagnosed can be treat-
able. Enzyme replacement therapy (ERT) with agalsidase beta 
has positive results, decreasing neuropathic pain (11) and 
reducing major organ complications (such as left ventricle 
hypertrophy) (12).
The screening of high-risk populations seems to be the best 
cost-effective strategy to diagnose new cases and intervene 
earlier. As musculoskeletal pain may be a chief complaint, 
children with joint pain may be considered a population at 
risk. Two types of pain in FD patients have been described: (1) 
episodes of burning pain in the extremities, radiating inwards, 
associated with low-grade fever; (2) acroparesthesias (chronic 
neuropathic pain in the extremities) (13, 14). These episodes 
tend to express early in the disease course (first and second 
decades of life) (8).
Juvenile idiopathic arthritis (JIA) is the commonest cause of 
chronic arthritis in childhood—0.07–4.01 per 1,000 children 
worldwide is affected (15). In the oligoarticular subtype (50–80% 
of all children with JIA), lower extremities are predominantly 
affected, with the knee being the most frequently involved joint, 
followed by the ankle (16). Also, in children and teenagers with 
enthesitis-related JIA, lower extremity pain is common (17). 
Furthermore, pain scores in Fabry disease were similar to those 
observed in a group of children with JIA (7).
The prevalence of FD among patients diagnosed as JIA is 
unknown. The correct diagnosis can prevent the progression of 
FD and avoid unjustifiable immunosuppression.
MaTerials anD MeThODs
We aimed to calculate the frequency of FD in a population of 
JIA patients by GLA genotyping. Carriers of Fabry’s-associated 
mutations were further characterized.
Children and young adults (mean age 17.7 years and 11 years 
of mean disease duration) from a JIA cohort of patients consecu-
tively included from Paediatric Rheumatology centres in Portugal 
Mainland and Islands. All patients were diagnosed by an expert 
physician in the field and classified according to the International 
League of Associations for Rheumatology (ILAR) criteria (18). 
Clinical and laboratorial information was recorded at regular 
time points, according to clinical practice, in the Portuguese 
nationwide register http://Reuma.pt.
Additionally, a questionnaire with clinical information and a 
laboratorial evaluation of relevant data in the context of JIA were 
also performed in these patients. Blood samples collected have been 
stored at the IMM Biobank, Lisbon Academic Medical Centre.
This study was submitted to the Local Ethics Committee, 
at Hospital de Santa Maria, Lisbon Academic Medical Centre. 
For being included in the study, parents and patients gave their 
informed written consent.
Molecular genetic testing to identify GLA mutations was per-
formed in the Centre of Histocompatibility in Coimbra. Direct 
sequencing was performed for samples from all patients in order 
to identify the precise mutation. Multiplex polymerase chain 
reactions with primers located in intron–exon boundaries were 
performed in order to allow sequencing of the complete coding 
region of GLA gene (seven exons). The GLA gene sequencing 
was performed in 3130 ABI sequencing platform (Applied 
Biosystems), and data were analyzed with SeqScape v3.0 and 
Geneious R9 software. Direct sequencing of the appropriate 
amplified fragment was a feasible strategy due to the development 
of rapid and sensitive automated sequencers. Control samples 
from healthy individuals were run in parallel with patients’ 
samples in order to confirm the consensus sequence for all the 
amplified exons.
resUlTs
Two hundred ninety-two patients (188 females, 104 males) from 
our JIA cohort were enrolled, including patients from Portugal 
Mainland and Azores and Madeira islands (Table 1). A female 
predominance was present (64.3%), and the mean current age 
and disease duration were 17.7 ± 9.2 and 11.0 ± 8.3 years, respec-
tively. The most frequent forms of JIA (ILAR Classification) were 
oligoarticular (persistent and extended), comprising almost 
half of the patients, followed by polyarticular seronegative form 
(16.8%).
Mutations were identified in five unrelated patients (all 
females)—Table  2. Four patients had the alpha-Gal A gene 
mutation D313Y (GAT to TAT at cDNA nucleotide 937), 
and one patient presented the mutation R118C (a missense 
mutation)—electropherogram (Figure  1). The mutations were 
found in patients from five centers in four different cities (Oporto, 
Coimbra, Lisbon, and Faro), showing a non-clustered distribu-
tion of the alterations D313Y and R118C.
Table 1 | clinical features of the Jia cohort.
cohort of Jia patients (n = 292) (%)
Female gender 64.3
Age [mean (SD)] 17.7 (9.2)
Age at diagnosis [mean (SD)] 8.0 (5.0)
Disease duration [mean (SD)] 11.0 (8.3)
Jia international league of associations 
for rheumatology classification
Persistent oligoarticular 33.0
Extended oligoarticular 15.8
Polyarticular RF− 16.8
Polyarticular RF+ 8.9
Psoriatic arthritis 5.5
Enthesitis-related JIA 12.0
Systemic JIA 7.9
Other features
Uveitis 13.7
Patients treated with cDMARDs 79.5
Patients treated with biologic DMARDs 20.2
cDMARDs, conventional drug modifying anti-rheumatic disease drugs; JIA, juvenile 
idiopathic arthritis; RF, rheumatoid factor.
Table 2 | clinical and demographic features of the patients with mutations.
Patient Mutation Form of juvenile idiopathic arthritis associated conditions current age 
(years)
age at disease onset (years) Treatment
1 R118C Persistent oligoarticular Uveitis 6 3 MTX, NSAID
2 D313Y Polyarticular RF− – 21 5 MTX, NSAID
3 D313Y Polyarticular RF− Cervical Spine Involvement 19 4 ETA, MTX, NSAID
4 D313Y Persistent oligoarticular – 25 9 MTX, NSAID
5 D313Y Persistent oligoarticular Uveitis 9 8 MTX, NSAID
ETA, etanercept; MTX, methotrexate; NSAID, non-steroid anti-inflammatory drugs; RF, rheumatoid factor.
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The patient with the R118C mutation is a 9-year-old girl who 
was diagnosed with oligoarticular JIA and uveitis when she was 
3 years old. Joint involvement was restricted to knee episodes of 
arthritis, managed initially with intra-articular steroid injections 
and since 2010 with subcutaneous methotrexate. She never had 
skin lesions and GI symptoms, and her electrocardiogram was 
normal. Her labs were unremarkable, except for positive antinu-
clear antibodies at a titer of 1/160 and increased inflammatory 
markers. She had normal levels of plasma globotriaosylsphingo-
sine (lyso-Gb3) (1.2 ng/mL, N < 1.8 ng/mL). Her family history is 
unremarkable for stroke at young age (<55 years), end-stage renal 
disease or premature death (before the fifth decade of life). Her 
mother suffers from Wolff–Parkinson–White (WPW) syndrome, 
and her father is type 2 diabetic non-insulin treated. One of her 
two sisters was born with hip dysplasia but with that exception 
her three siblings (aged 15, 16, and 18) are healthy.
The clinical history from the four patients with D313Y muta-
tion was also revised. Patients were unremarkable for pain with 
neuropathic features, skin lesions, and GI symptoms. None of the 
JIA patients suffered from stroke, myocardiopathy, or chronic 
kidney disease. Their family members did not show any relevant 
finding, including chronic kidney disease, cardiac anomalies, and 
cerebrovascular events at young age.
DiscUssiOn
To our knowledge, this was the first study in which FD was 
screened in a large cohort of JIA patients. No “classic” pathogenic 
FD mutations were found. The late-onset FD-associated mutation 
(R118C) was reported in a frequency of 0.34% (1 in 292 individu-
als) within this nationwide JIA cohort.
Several screenings of FD have been pursued in young adults 
with stroke, including one in a Portuguese population (19), in 
hemodialyzed patients (20) and in patients with hypertrophic 
cardiomyopathy (21). Our cohort is the youngest to be screened 
until the present moment, as far as we know. Screening of young 
populations for FD may become particularly important as some 
advocate initiation of ERT in children (22), although the inter-
national position paper (2015) adopt a more cautious view (23).
The mutational analysis through direct sequencing performed 
to screen for FD assured the same sensitivity for both genders, 
overcoming the limitations of alpha-Gal activity assays to diag-
nose FD in females.
The most commonly mutation found in our population was 
D313Y, which pathological significance for FD has been doubted, 
because in general D313Y patients do not present clinical mani-
festations typical of FD (24). Also, it was also proven that Gb3 
does not accumulate in the lysosomes of D313Y patients (24).
R118C mutation was reported for the first time in a screen-
ing of 37,104 consecutive newborn males in Italy (25). R118C 
mutation was found in a neonate deficient in alpha-Gal A activity 
(double assay). This missense mutation had structural character-
istics and in vitro overexpression levels similar to those of known 
later-onset missense mutations (25).
As our patient is a female and R188C is a mutation associated 
to late-onset FD, we cannot ascertain a final diagnosis of FD.
The patient and her family are under further clinical investiga-
tion. According to diagnostic criteria (15), there is no need to 
access enzymatic activity (as it can be normal in a female patient). 
It should be verified if classical symptoms develop or if her par-
ents have definite FD diagnosis carrying the same GLA mutation.
The patient’s mother suffers from WPW syndrome, and an 
association of WPW with autosomal dominant familial hyper-
trophic cardiomyopathy has been described (26). However, there 
are no reports of a direct association of FD and WPW.
A low threshold for FD in JIA patients should be warranted, as 
pain maybe an initial manifestation during the first decades of life 
(7, 8). Also, a family history of strokes at young age, early onset 
chronic kidney disease, or myocardiopathy should further elevate 
the clinical suspicion.
FigUre 1 | electropherogram of the r118c mutation.
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Late manifestations of FD, namely, poststroke status, end-
stage renal disease, and hypertrophic myocardiopathy, are 
associated with high morbidity and mortality. On the contrary, 
early diagnosis of FD can lead to implementation of a specific 
therapy and allow for the study of their families and respective 
early treatment if justified. Therefore, finding strategies to screen 
younger populations, in whom such events could be prevented, 
seems crucial.
Cost-effectiveness of population screening, even in high-risk 
groups is difficult to estimate, considering the high direct and 
indirect costs of this disease in late stages, but also the high cost 
of enzyme replacement therapies.
Further studies should assess optimal ways of defining high-
risk young populations, maybe by combining family history with 
the presence of symptoms, such as those occurring in JIA.
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